JP2013501814A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501814A5
JP2013501814A5 JP2012524903A JP2012524903A JP2013501814A5 JP 2013501814 A5 JP2013501814 A5 JP 2013501814A5 JP 2012524903 A JP2012524903 A JP 2012524903A JP 2012524903 A JP2012524903 A JP 2012524903A JP 2013501814 A5 JP2013501814 A5 JP 2013501814A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
h7cr
interaction
activity
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012524903A
Other languages
English (en)
Japanese (ja)
Other versions
JP5883384B2 (ja
JP2013501814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/045479 external-priority patent/WO2011020024A2/en
Publication of JP2013501814A publication Critical patent/JP2013501814A/ja
Publication of JP2013501814A5 publication Critical patent/JP2013501814A5/ja
Application granted granted Critical
Publication of JP5883384B2 publication Critical patent/JP5883384B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012524903A 2009-08-13 2010-08-13 免疫機能を調節する方法 Expired - Fee Related JP5883384B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23365009P 2009-08-13 2009-08-13
US61/233,650 2009-08-13
US28995109P 2009-12-23 2009-12-23
US61/289,951 2009-12-23
PCT/US2010/045479 WO2011020024A2 (en) 2009-08-13 2010-08-13 Methods of modulating immune function

Publications (3)

Publication Number Publication Date
JP2013501814A JP2013501814A (ja) 2013-01-17
JP2013501814A5 true JP2013501814A5 (https=) 2013-10-03
JP5883384B2 JP5883384B2 (ja) 2016-03-15

Family

ID=43297014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012524903A Expired - Fee Related JP5883384B2 (ja) 2009-08-13 2010-08-13 免疫機能を調節する方法

Country Status (7)

Country Link
US (3) US8840889B2 (https=)
EP (2) EP2464661B1 (https=)
JP (1) JP5883384B2 (https=)
AU (2) AU2010282340B2 (https=)
CA (1) CA2769822C (https=)
ES (1) ES2666152T3 (https=)
WO (1) WO2011020024A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266495A1 (en) * 2004-05-21 2010-10-21 Brigham Young University Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
US7520860B2 (en) 2005-04-13 2009-04-21 Marie G. Johnson Detection of coronary artery disease using an electronic stethoscope
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
ES2666152T3 (es) * 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
TWI556194B (zh) * 2012-06-29 2016-11-01 希科母股份有限公司 對象檢出裝置、對象檢出方法及對象檢出用電腦程式
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
MX2015008117A (es) * 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
US20140205609A1 (en) * 2013-01-24 2014-07-24 Fred T. Valentine Methods for inducing systemic immune responses to cancer
WO2014133728A2 (en) 2013-03-01 2014-09-04 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
BR112015029395A2 (pt) * 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20150291606A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
US10280208B2 (en) * 2014-04-30 2019-05-07 Albert Einstein College Of Medicine TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
WO2015187359A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック, インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
TWI719970B (zh) * 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對icos之抗體
KR102658190B1 (ko) * 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
EP3283508B1 (en) * 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
ITUB20151014A1 (it) 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
US11547739B2 (en) * 2015-12-16 2023-01-10 La Jolla Institute For Allergy And Immunology Peptides and methods related to ICOS signaling
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
EP4706777A2 (en) 2016-04-15 2026-03-11 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN106755372B (zh) * 2016-12-12 2020-03-31 青岛泱深生物医药有限公司 一种分子标志物在口腔鳞状细胞癌诊断和治疗中的应用
US11192933B2 (en) * 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019005817A2 (en) * 2017-06-26 2019-01-03 Bio-Techne Corporation HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SMT202600062T1 (it) * 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US20190216840A1 (en) * 2018-01-12 2019-07-18 Genome And Company Novel use of kirrel2 and kirrel2 inhibitor
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス, インコーポレイテッド B7−h4抗体製剤
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
KR20210007959A (ko) * 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
CN108872588B (zh) * 2018-06-14 2021-05-28 华南农业大学 一种与种公猪繁殖性能密切相关的精子蛋白标记spaca4及其应用
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
EP3850009A1 (en) * 2018-08-21 2021-07-21 NGM Biopharmaceuticals, Inc. B7-h7-binding agents and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
KR20210143868A (ko) * 2019-03-26 2021-11-29 포티 세븐, 인코포레이티드 암 치료용 다중특이성 제제
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CN119040454B (zh) * 2024-09-27 2026-04-21 华南农业大学 Slc26a2基因作为肉鸡胫骨软骨发育不良标志物的应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (https=) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
CA2389916A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
PT1218504E (pt) * 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
EP2341075A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6987024B1 (en) 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
AU2001264747A1 (en) 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1892251A3 (en) 2000-06-06 2008-12-31 Brystol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
CA2412377A1 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
AU7298201A (en) * 2000-06-23 2002-01-08 Biogen Inc Gp286 nucleic acids and polypeptides
CA2406649A1 (en) * 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6891030B2 (en) 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
AU2001286205A1 (en) 2000-09-12 2002-03-26 Kirin Beer Kabushiki Kaisha Novel dendritic cell wall membrane and use thereof
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
EP1399187A4 (en) 2000-10-18 2005-09-21 Sloan Kettering Inst Cancer APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7651541B2 (en) 2001-01-10 2010-01-26 State Line Holdings, LLC Chemical change agent
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1401999A4 (en) 2001-05-25 2005-09-14 Amgen Inc PROTEIN-2 MOLECULES ASSOCIATED WITH B7 AND USE THEREOF
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003014293A2 (en) 2001-08-02 2003-02-20 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use
CA2475356A1 (en) 2002-02-12 2003-08-21 Raven Biotechnologies, Inc. Human fetal bladder-derived epithelial cells
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004014292A2 (en) 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20040028685A1 (en) 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
MXPA04012664A (es) 2002-06-19 2005-08-15 Raven Biotechnologies Inc Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo.
US7304149B2 (en) 2002-06-20 2007-12-04 Washington University In St. Louis BTLA nucleic acids
WO2004001004A2 (en) 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
WO2004010935A2 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
CA2606334A1 (en) * 2005-05-12 2006-11-12 Zymogenetics, Inc. Methods of using phhla2 to co-stimulate t-cells
EP2345412A1 (en) 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
EP2109455A2 (en) * 2006-12-27 2009-10-21 The Johns Hopkins University Compositions and methods for stimulating an immune response
WO2009089149A1 (en) 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
ES2666152T3 (es) * 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
MX2015008117A (es) * 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.

Similar Documents

Publication Publication Date Title
JP2013501814A5 (https=)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NZ582150A (en) Antibodies to human programmed death receptor pd-1
JP2009286795A5 (https=)
JP2014169326A5 (https=)
CY1119852T1 (el) Σκευασμα αντισωματος και θεραπευτικα σχηματα
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA201400855A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
EA201290589A1 (ru) Cd127-связывающие белки
JP2014530226A5 (https=)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
CY1111011T1 (el) Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
JP2012021001A5 (https=)
RU2013151455A (ru) Антитела и другие молекулы, которые связывают в7-н1 и pd-1
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
JP2009539841A5 (https=)
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
JP2010500370A5 (https=)
JP2014513722A5 (https=)
JP2013537539A5 (https=)